{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/unlocking-long-term-value-clinical-trial-productivity-considerations-emerging-biotechs#webpage",
"url": "https://www.fortrea.com/insights/unlocking-long-term-value-clinical-trial-productivity-considerations-emerging-biotechs",
"name": "Unlocking long-term value: Clinical trial productivity considerations for emerging biotechs",
"description": "This Fortrea article explores how clinical trial productivity can serve as a strategic value driver for emerging biotech companies beyond achieving scientific and clinical milestones. While many biotechs focus on rapidly reaching proof-of-concept to secure funding, partnerships, acquisitions, or commercialization opportunities, short-term development decisions can unintentionally create productivity gaps that affect long-term asset value. The article examines how inefficiencies in trial design, operational execution, and data strategy can contribute to delayed timelines, increased development costs, and reduced attractiveness to investors and collaborators. It highlights the importance of evaluating productivity at key clinical development milestones and demonstrates how collaboration with contract research organizations (CROs) can help identify opportunities to reduce trial burden, improve trial performance, accelerate development timelines, and strengthen both the clinical and commercial profile of an asset. Through a focus on long-term value creation, emerging biotechs can make more informed development decisions that support financial objectives while positioning therapies for future investment, licensing, acquisition, and commercialization success."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Unlocking long-term value: Clinical trial productivity considerations for emerging biotechs",
"item": "https://www.fortrea.com/insights/unlocking-long-term-value-clinical-trial-productivity-considerations-emerging-biotechs"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/unlocking-long-term-value-clinical-trial-productivity-considerations-emerging-biotechs#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/unlocking-long-term-value-clinical-trial-productivity-considerations-emerging-biotechs#webpage"
},
"headline": "Clinical Trial Productivity for Emerging Biotechs: Unlocking Long-Term Asset Value Through Strategic Development Decisions | Fortrea Article",
"description": "This Fortrea article explores how clinical trial productivity can serve as a strategic value driver for emerging biotech companies beyond achieving scientific and clinical milestones. While many biotechs focus on rapidly reaching proof-of-concept to secure funding, partnerships, acquisitions, or commercialization opportunities, short-term development decisions can unintentionally create productivity gaps that affect long-term asset value. The article examines how inefficiencies in trial design, operational execution, and data strategy can contribute to delayed timelines, increased development costs, and reduced attractiveness to investors and collaborators. It highlights the importance of evaluating productivity at key clinical development milestones and demonstrates how collaboration with contract research organizations (CROs) can help identify opportunities to reduce trial burden, improve trial performance, accelerate development timelines, and strengthen both the clinical and commercial profile of an asset. Through a focus on long-term value creation, emerging biotechs can make more informed development decisions that support financial objectives while positioning therapies for future investment, licensing, acquisition, and commercialization success.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-02/clinical-trial-productivity-emerging-biotechs.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-02-03",
"dateModified": "2026-02-03",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-02/clinical-trial-productivity-emerging-biotechs.pdf",
"encodingFormat": "application/pdf"
}
}
]
}